Impact of γ-chain cytokines on T cell homeostasis in HIV-1 infection: Therapeutic implications: Symposium

Journal of Internal Medicine

Volumn 267, Issue 5, 2010, Pages 502-514

  Gougeon, M L ^a   Chiodi, F ^b  

^a INSTITUT PASTEUR   (France)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

chain cytokines; Apoptosis; HIV 1; T cell homeostasis; T cell reconstitution

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LOSS; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFECTION RESISTANCE; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS REPLICATION;

ANTI-RETROVIRAL AGENTS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHRONIC DISEASE; HIV INFECTIONS; HIV-1; HOMEOSTASIS; HUMANS; INTERLEUKIN-2; INTERLEUKIN-7; RECEPTORS, CYTOKINE;

EID: 77950512073     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02221.x     Document Type: Conference Paper

References (144)

1. + T cell expansion and function. J Exp Med 2005 201 : 139 148. (Pubitemid 40130091)
2. Takeshita T, Asao H, Ohtani K et al. Cloning of the gamma chain of the human IL-2 receptor. Science 1992 257 : 379 382.
3. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998 352 : 1725 1730. (Pubitemid 28534954)
4. + T-cell function with antiretroviral therapies. AIDS 2001 15 (Suppl. 2 S11 5.
5. Andersson J, Fehniger TE, Patterson BK et al. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 1998 12 : F123 9. (Pubitemid 28330715)
6. Gougeon ML, Lecoeur H, Sasaki Y. Apoptosis and the CD95 system in HIV disease: impact of highly active anti-retroviral therapy (HAART). Immunol Lett 1999 66 : 97 103. (Pubitemid 29136824)
7. + (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 2001 98 : 3016 3021.
8. + T cell responses induced by dendritic cells generated in the presence of IFN-alpha. J Immunol 2004 172 : 7832 7840. (Pubitemid 38747651)
9. Gougeon ML. Apoptosis as an HIV strategy to escape immune attack. Nat Rev Immunol 2003 3 : 392 404.
10. Douek DC, McFarland RD, Keiser PH et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998 396 : 690 695.
11. + T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004 200 : 761 770. (Pubitemid 39299462)
12. + T cell depletion and viral replication in SIV infection. Science 1998 280 : 427 431.
13. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004 200 : 749 759.
14. + T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003 77 : 11708 11717. (Pubitemid 37271669)
15. + T cells. Nature 2005 434 : 1148 1152. (Pubitemid 40663495)
16. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997 16 : 83 92. (Pubitemid 27465572)
17. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006 12 : 1365 1371.
18. + T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008 197 : 126 133. (Pubitemid 351263476)
19. + T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 2008 22 : 2035 2038.
20. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003 54 : 535 551. (Pubitemid 37386411)
21. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994 68 : 6103 6110. (Pubitemid 24258634)
22. Koup RA, Safrit JT, Cao Y et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994 68 : 4650 4655. (Pubitemid 24183063)
23. Leslie AJ, Pfafferott KJ, Chetty P et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004 10 : 282 289. (Pubitemid 38667619)
24. Price DA, Goulder PJ, Klenerman P et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A 1997 94 : 1890 1895. (Pubitemid 27113932)
25. + T cell frequencies. J Infect Dis 2004 190 : 713 721. (Pubitemid 39050001)
26. Jin X, Bauer DE, Tuttleton SE et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999 189 : 991 998. (Pubitemid 29149355)
27. Veazey RS, Gauduin MC, Mansfield KG et al. Emergence and kinetics of simian immunodeficiency virus-specific CD8(+) T cells in the intestines of macaques during primary infection. J Virol 2001 75 : 10515 10519.
28. Chun TW, Nickle DC, Justement JS et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008 197 : 714 720.
29. + T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008 29 : 1009 1021.
30. Betts MR, Harari A. Phenotype and function of protective T cell immune responses in HIV. Curr Opin HIV AIDS 2008 3 : 349 355. (Pubitemid 351521020)
31. Ferre AL, Hunt PW, Critchfield JW et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009 113 : 3978 3989.
32. Turk G, Gherardi MM, Laufer N et al. Magnitude, breadth, and functional profile of T-cell responses during human immunodeficiency virus primary infection with B and BF viral variants. J Virol 2008 82 : 2853 2866. (Pubitemid 351329176)
33. McNeil AC, Shupert WL, Iyasere CA et al. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci U S A 2001 98 : 13878 13883.
34. Ledru E, Lecoeur H, Garcia S, Debord T, Gougeon ML. Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: correlation with Bcl-2 expression and consequences for AIDS pathogenesis. J Immunol 1998 160 : 3194 3206. (Pubitemid 28164708)
35. Brooks DG, Teyton L, Oldstone MB, McGavern DB. Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. J Virol 2005 79 : 10514 10527. (Pubitemid 41098591)
36. Day CL, Kaufmann DE, Kiepiela P et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006 443 : 350 354. (Pubitemid 44435155)
37. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006 439 : 682 687. (Pubitemid 43237609)
38. Velu V, Titanji K, Zhu B et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009 458 : 206 210.
39. + T cell survival in HIV infection. J Exp Med 2006 203 : 2281 2292. (Pubitemid 44498363)
40. + T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 2007 109 : 4671 4678. (Pubitemid 46827757)
41. + T cells leads to reversible immune dysfunction. Nat Med 2006 12 : 1198 1202. (Pubitemid 44527357)
42. + T cell exhaustion during chronic viral infection. Immunity 2007 27 : 670 684. (Pubitemid 47615511)
43. Clerici M, Wynn TA, Berzofsky JA et al. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest 1994 93 : 768 775. (Pubitemid 24072820)
44. de Waal Malefyt R, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991 174 : 915 924.
45. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006 12 : 1301 1309. (Pubitemid 44706933)
46. Kinter AL, Hennessey M, Bell A et al. CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 2004 200 : 331 343. (Pubitemid 39031252)
47. + regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 2004 104 : 3249 3256. (Pubitemid 39507143)
48. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 2007 7 : 875 888. (Pubitemid 350006238)
49. Nilsson J, Boasso A, Velilla PA et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 2006 108 : 3808 3817. (Pubitemid 44864563)
50. + T cell memory by promoting the generation of IL-7R alpha-expressing cells. J Exp Med 2007 204 : 547 557. (Pubitemid 46457078)
51. + T lymphocytes during HIV infection. J Immunol 1996 156 : 2282 2293. (Pubitemid 26087459)
52. Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC, Gougeon ML. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000 95 : 3191 3198. (Pubitemid 30321172)
53. Gougeon ML, Lecoeur H, Boudet F et al. Lack of chronic immune activation in HIV-infected chimpanzees correlates with the resistance of T cells to Fas/Apo-1 (CD95)-induced apoptosis and preservation of a T helper 1 phenotype. J Immunol 1997 158 : 2964 2976. (Pubitemid 127470560)
54. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008 26 : 453 479.
55. Reya T, Yang-Snyder JA, Rothenberg EV, Carding SR. Regulated expression and function of CD122 (interleukin-2/interleukin-15R-beta) during lymphoid development. Blood 1996 87 : 190 201. (Pubitemid 26011833)
56. Hanke T, Mitnacht R, Boyd R, Hunig T. Induction of interleukin 2 receptor beta chain expression by self-recognition in the thymus. J Exp Med 1994 180 : 1629 1636. (Pubitemid 24328555)
57. Hemar A, Subtil A, Lieb M, Morelon E, Hellio R, Dautry-Varsat A. Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains. J Cell Biol 1995 129 : 55 64.
58. Johnson K, Choi Y, Wu Z et al. Soluble IL-2 receptor beta and gamma subunits: ligand binding and cooperativity. Eur Cytokine Netw 1994 5 : 23 34. (Pubitemid 24133288)
59. Cantrell DA, Smith KA. The interleukin-2 T-cell system: a new cell growth model. Science 1984 224 : 1312 1316.
60. Smith KA. The interleukin 2 receptor. Annu Rev Cell Biol 1989 5 : 397 425.
61. Zola H, Koh LY, Mantzioris BX, Rhodes D. Patients with HIV infection have a reduced proportion of lymphocytes expressing the IL2 receptor p55 chain (TAC, CD25). Clin Immunol Immunopathol 1991 59 : 16 25.
62. David D, Bani L, Moreau JL et al. Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. Proc Natl Acad Sci U S A 1998 95 : 11348 11353. (Pubitemid 28450131)
63. David D, Keller H, Nait-Ighil L et al. Involvement of Bcl-2 and IL-2R in HIV-positive patients whose CD4 cell counts fail to increase rapidly with highly active antiretroviral therapy. AIDS 2002 16 : 1093 1101. (Pubitemid 34533847)
64. Jiang Q, Li WQ, Aiello FB et al. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev 2005 16 : 513 533. (Pubitemid 41022015)
65. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003 4 : 1191 1198. (Pubitemid 37540688)
66. Li J, Huston G, Swain SL. IL-7 promotes the transition of CD4 effectors to persistent memory cells. J Exp Med 2003 198 : 1807 1815. (Pubitemid 38032114)
67. Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 2005 174 : 6571 6576.
68. Fry TJ, Mackall CL. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol 2001 22 : 564 571. (Pubitemid 33016404)
69. Napolitano LA, Grant RM, Deeks SG et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med 2001 7 : 73 9.
70. Llano A, Barretina J, Gutierrez A et al. Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals. J Virol 2001 75 : 10319 10325. (Pubitemid 32948062)
71. Rethi B, Fluur C, Atlas A et al. Loss of IL-7Ralpha is associated with CD4 T-cell depletion, high interleukin-7 levels and CD28 down-regulation in HIV infected patients. AIDS 2005 19 : 2077 2086. (Pubitemid 41668995)
72. Boutboul F, Puthier D, Appay V et al. Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMV. AIDS 2005 19 : 1981 1986. (Pubitemid 41669022)
73. Sasson SC, Zaunders JJ, Zanetti G et al. Increased plasma interleukin-7 level correlates with decreased CD127 and Increased CD132 extracellular expression on T cell subsets in patients with HIV-1 infection. J Infect Dis 2006 193 : 505 514. (Pubitemid 43202741)
74. Beq S, Bugault F, Colle JH, Lambotte O, Delfraissy JF, Theze J. Anti-retroviral therapy in HIV-infected patients: in vitro effects of AZT and saquinavir on the response of CD4 and CD8 lymphocytes to interleukin-7. Eur Cytokine Netw 2005 16 : 293 299. (Pubitemid 350056545)
75. Pericle F, Pinto LA, Hicks S et al. HIV-1 infection induces a selective reduction in STAT5 protein expression. J Immunol 1998 160 : 28 31. (Pubitemid 28116711)
76. Bovolenta C, Camorali L, Lorini AL et al. Constitutive activation of STATs upon in vivo human immunodeficiency virus infection. Blood 1999 94 : 4202 4209.
77. Kryworuchko M, Pasquier V, Keller H et al. Defective interleukin-2- dependent STAT5 signalling in CD8 T lymphocytes from HIV-positive patients: restoration by antiretroviral therapy. AIDS 2004 18 : 421 426. (Pubitemid 38365868)
78. Prost S, Le Dantec M, Auge S et al. Human and simian immunodeficiency viruses deregulate early hematopoiesis through a Nef/PPARgamma/STAT5 signaling pathway in macaques. J Clin Invest 2008 118 : 1765 1775. (Pubitemid 351632379)
79. Selliah N, Zhang M, DeSimone D et al. The gammac-cytokine regulated transcription factor, STAT5, increases HIV-1 production in primary CD4 T cells. Virology 2006 344 : 283 291. (Pubitemid 43049616)
80. Sousa AE, Chaves AF, Loureiro A, Victorino RM. Comparison of the frequency of interleukin (IL)-2-, interferon-gamma-, and IL-4-producing T cells in 2 diseases, human immunodeficiency virus types 1 and 2, with distinct clinical outcomes. J Infect Dis 2001 184 : 552 559. (Pubitemid 32783545)
81. Davey RT Jr., Chaitt DG, Albert JM et al. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999 179 : 849 858.
82. Davey RT Jr., Chaitt DG, Piscitelli SC et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 1997 175 : 781 789. (Pubitemid 27142948)
83. Kovacs JA, Vogel S, Albert JM et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996 335 : 1350 1356. (Pubitemid 26360453)
84. Levy Y, Capitant C, Houhou S et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Lancet 1999 353 : 1923 1929. (Pubitemid 29255705)
85. + T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 2005 115 : 2139 2148.
86. Levy Y, Durier C, Krzysiek R et al. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 2003 17 : 343 351. (Pubitemid 36223259)
87. Durier C, Capitant C, Lascaux AS et al. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials). AIDS 2007 21 : 1887 1897. (Pubitemid 47329765)
88. Gougeon ML, Rouzioux C, Liberman I et al. Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patients. AIDS 2001 15 : 1729 1731. (Pubitemid 32918129)
89. Sereti I, Martinez-Wilson H, Metcalf JA et al. Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. Blood 2002 100 : 2159 2167. (Pubitemid 35001252)
90. Sereti I, Imamichi H, Natarajan V et al. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 2005 115 : 1839 1847.
91. + T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 2004 104 : 775 780. (Pubitemid 38970572)
92. + cell count of 300/mm3: primary results of the ESPRIT study [abstract 90aLB]. The 16th Conference on Retroviruses and Opportunistic Infections (Montreal) (CROI)
93. 3: primary results of the SILCAAT study [abstract 90bLB]. The 16th Conference on Retroviruses and Opportunistic Infections (Montreal) (CROI)
94. Kinter AL, Godbout EJ, McNally JP et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008 181 : 6738 6746.
95. Molina JM, Levy Y, Fournier I et al. Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119). J Infect Dis 2009 200 : 206 215.
96. Mackall CL, Fry TJ, Bare C, Morgan P, Galbraith A, Gress RE. IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood 2001 97 : 1491 1497. (Pubitemid 32183777)
97. Fry TJ, Christensen BL, Komschlies KL, Gress RE, Mackall CL. Interleukin-7 restores immunity in athymic T-cell-depleted hosts. Blood 2001 97 : 1525 1533.
98. Capitini CM, Chisti AA, Mackall CL. Modulating T-cell homeostasis with IL-7: preclinical and clinical studies. J Intern Med 2009 266 : 141 153.
99. Sportes C, Hakim FT, Memon SA et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008 205 : 1701 1714. (Pubitemid 351962032)
100. Beq S, Nugeyre MT, Ho Tsong Fang R et al. IL-7 induces immunological improvement in SIV-infected rhesus macaques under antiviral therapy. J Immunol 2006 176 : 914 922. (Pubitemid 43099689)
101. Nugeyre MT, Monceaux V, Beq S et al. IL-7 stimulates T cell renewal without increasing viral replication in simian immunodeficiency virus-infected macaques. J Immunol 2003 171 : 4447 4453. (Pubitemid 37238725)
102. Fry TJ, Moniuszko M, Creekmore S et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 2003 101 : 2294 2299. (Pubitemid 36302072)
103. + recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr 2008 48 : 541 546.
104. Levy Y, Lacabaratz C, Weiss L et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009 119 : 997 1007.
105. Sereti I, Dunham RM, Spritzler J et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009 113 : 6304 6314.
106. Smithgall MD, Wong JG, Critchett KE, Haffar OK. IL-7 up-regulates HIV-1 replication in naturally infected peripheral blood mononuclear cells. J Immunol 1996 156 : 2324 2330. (Pubitemid 26087464)
107. Wang FX, Xu Y, Sullivan J et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005 115 : 128 137. (Pubitemid 40385513)
108. Scripture-Adams DD, Brooks DG, Korin YD, Zack JA. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 2002 76 : 13077 13082.
109. Beq S, Rozlan S, Gautier D et al. Injection of glycosylated recombinant simian IL-7 provokes rapid and massive T-cell homing in rhesus macaques. Blood 2009 114 : 816 825.
110. + T cells: IL-2 and IL-7 differentially regulate the balance between proliferation and Fas-mediated apoptosis. J Immunol 2003 171 : 61 8. (Pubitemid 36745273)
111. Fluur C, De Milito A, Fry TJ et al. Potential role for IL-7 in Fas-mediated T cell apoptosis during HIV infection. J Immunol 2007 178 : 5340 5350. (Pubitemid 46595320)
112. Rethi B, Vivar N, Sammicheli S et al. Priming of T cells to Fas-mediated proliferative signals by interleukin-7. Blood 2008 112 : 1195 1204.
113. Rethi B, Vivar N, Sammicheli S, Chiodi F. Limited efficiency of endogenous interleukin-7 levels in T cell reconstitution during HIV-1 infection: will exogenous interleukin-7 therapy work? AIDS 2009 27 : 745 755.
114. Lori F. Fas, IL-7, and T cells: live and let die. Blood 2008 112 : 930 931.
115. + T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. Blood 2007 109 : 2086 2088. (Pubitemid 46348209)
116. Benoit A, Abdkader K, Sirskyj D et al. Inverse association of repressor growth factor independent-1 with CD8 T cell interleukin (IL)-7 receptor [alpha] expression and limited signal transducers and activators of transcription signaling in response to IL-7 among [gamma]-chain cytokines in HIV patients. AIDS 2009 23 : 1341 1347.
117. + T cells requires PI3K- and STAT5-dependent expression of IL-2Rbeta that is defective in HIV-infected patients. J Immunol 2008 180 : 7221 7229.
118. + T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol 2001 13 : 483 488. (Pubitemid 32728483)
119. Lederman MM, Connick E, Landay A et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998 178 : 70 9. (Pubitemid 28328078)
120. Schooley RT. Longer-term immunologic effects and side effects of successful antiretroviral therapy. Clin Infect Dis 1999 29 : 12 8.
121. + T-cell expansions in patients with human immunodeficiency virus infection receiving highly active combination therapy. Blood 2001 97 : 1787 1795. (Pubitemid 32217247)
122. Porter BO, Shen J, Kovacs JA et al. Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels. AIDS 2009 23 : 2015 2019.
123. Kovacs JA, Vogel S, Metcalf JA et al. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy. Eur J Immunol 2001 31 : 1351 1360. (Pubitemid 32454683)
124. de Oliveira Pinto LM, Lecoeur H, Ledru E, Rapp C, Patey O, Gougeon ML. Lack of control of T cell apoptosis under HAART. Influence of therapy regimen in vivo and in vitro. AIDS 2002 16 : 329 339. (Pubitemid 34165363)
125. Herbeuval JP, Nilsson J, Boasso A et al. HAART reduces death ligand but not death receptors in lymphoid tissue of HIV-infected patients and simian immunodeficiency virus-infected macaques. AIDS 2009 23 : 35 40.
126. Amendola A, Poccia F, Martini F et al. Decreased CD95 expression on naive T cells from HIV-infected persons undergoing highly active anti-retroviral therapy (HAART) and the influence of IL-2 low dose administration. Irhan Study Group. Clin Exp Immunol 2000 120 : 324 332. (Pubitemid 30304229)
127. Pandolfi F, Pierdominici M, Marziali M et al. Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART. Clin Immunol 2000 94 : 153 159. (Pubitemid 30141743)
128. Read SW, Lempicki RA, Di Mascio M et al. CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients. J Infect Dis 2008 198 : 843 850.
129. Sereti I, Herpin B, Metcalf JA et al. CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients. AIDS 2001 15 : 1765 1775. (Pubitemid 32939236)
130. Smith KY, Valdez H, Landay A et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis 2000 181 : 141 147. (Pubitemid 30049042)
131. + T cells in vivo after IL-2 treatment of patients with HIV infection. Proc Natl Acad Sci U S A 2002 99 : 10712 10717.
132. Rinaldo CR Jr., Liebmann JM, Huang XL et al. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 1999 179 : 329 336.
133. Pontesilli O, Kerkhof-Garde S, Notermans DW et al. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999 180 : 76
134. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998 4 : 953 956.
135. + T cell proliferation in HIV infection. J Med Virol 2006 78 : 1147 1157. (Pubitemid 44182230)
136. + T cell polyfunctionality, proliferation and cytotoxicity are not restored by antiretroviral therapy. J Virol 2009 83 : 11876 11889.
137. + Treg in HIV-1-infected patients with low CD4 counts. Eur J Immunol 2009 39 : 301 309.
138. + T cells in HIV-1-infected typical progressors, but not in long-term non-progressors. Immunology 2009 128 : e366 75.
139. Lim A, Tan D, Price P et al. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy. AIDS 2007 21 : 1525 1534. (Pubitemid 47075472)
140. Hazenberg MD, Stuart JW, Otto SA et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000 95 : 249 255.
141. Marchetti G, Gori A, Casabianca A et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 2006 20 : 1727 1736. (Pubitemid 44299364)
142. Rosenberg ES, Altfeld M, Poon SH et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000 407 : 523 526.
143. McCune JM, Hanley MB, Cesar D et al. Factors influencing T-cell turnover in HIV-1-seropositive patients. J Clin Invest 2000 105 : R1 8. (Pubitemid 30146516)
144. Bucy RP, Hockett RD, Derdeyn CA et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999 103 : 1391 1398.